To evaluate the efficacy of levetiracetam in cases of refractory primary generalised epilepsy. Methods: Three patients with refractory primary generalised epilepsy were treated with levetiracetam monotherapy; one with absence seizures, myoclonic jerks and generalised tonic-clonic (GTC) seizures one with myoclonic jerks and GTC seizures, and one with only GTC seizures. All three patients had generalised spike wave on the EEG and had failed at least three antiepileptic drugs (AEDs) before trying levetiracetam. Results: All three patients tolerated levetiracetam well and became seizure free for at least 6 months. Therapeutic doses of levetiracetam ranged from 1250 to 3000 mg/day. Conclusion: Levetiracetam, a new AED with a novel mechanism(s) of action, should be considered for patients with refractory primary generalised epilepsy.
INTRODUCTION
Conventional treatment for primary generalised epilepsy includes valproic acid and more recently, lamotrigine and topiramate 1 . Because carbamazepine, gabapentin, phenytoin, tiagabine and vigabatrin may aggravate absence seizures or myoclonic jerks, their role in primary generalised epilepsy is limited 2 .
Three patients with primary generalised epilepsy refractory to other antiepileptic drugs (AEDs) were treated with levetiracetam monotherapy (Table 1) . Levetiracetam received US Food and Drug Administration (FDA) approval in November 1999 as adjunctive treatment for partial onset seizures in adults based on three multicentre, randomised, double-blind, placebo-controlled clinical studies in 904 patients with refractory partial seizures with or without secondary generalisation for at least 2 years [3] [4] [5] . The number of patients who achieved a seizure reduction of at least 50% compared to baseline was 28.6% of patients on 1000 mg/day, 35.2% on 2000 mg/day and 39.5% on 3000 mg/day 6 . Adverse events included somnolence (14.8%), asthenia (14.7%), infection (13.4%), behavioural problems (13.3%), dizziness (8.8%), pharyngitis (6.1%) and rhinitis (4.4%) 7 . The majority of adverse events were mild to moderate.
Since these pivotal trials, over 100 000 patients in the US have been treated with levetiracetam 8 .
Case #1
MS was a 15-year-old left-handed boy whose seizures began with a convulsion at age 12. While awake but sleep deprived, he had two more convulsions a few months later prompting him to seek medical attention. His family history was notable for a brother with seizures that began at age 3 and resolved at age 13. MS had no history of myoclonic jerks or staring spells. Development, neurological examination, CT and brain MRI were normal. His first EEG was normal; however, the second revealed frequent bursts of 2-3 Hz generalised spike and wave lasting up to 15 seconds. MS began treatment with carbamazepine 100 mg b.i.d. Over the first year, he had several convulsions, often associated with non-compliance. He switched to delayed release carbamazepine (Carbatrol), 300 mg b.i.d., and had trough levels of 8.6 g/ml. He continued to have occasional breakthrough seizures and divalproex sodium was substituted for carbamazepine. At levels of 120 g/ml, he was seizure free, but complained of fatigue and hepatic enzymes were slightly elevated, aspartate aminotransferase (AST) 120 Karmen units (0-34) and alanine aminotransferase (ALT) 93 Karmen units (0-40).
The patient developed a viral syndrome, and was unable to take the valproate. His valproate level dropped to 50 g/ml, and he developed generalised tonic-clonic (GTC) status epilepticus. Divalproex sodium was tapered and he began topiramate. Dosages were increased to 200 mg b.i.d. The patient complained of fatigue and cognitive slowing. Topiramate was tapered and he started levetiracetam at 250 mg b.i.d., which was increased to 1500 mg b.i.d. He has been seizure free for 9 months since beginning levetiracetam and is back to normal school and sports activity.
Case #2
RR was a 26-year-old right-handed man who had his first GTC seizure during sleep at age 3. At age 5, he had a convulsion while awake and was placed on phenobarbital. During childhood, he developed absence seizures. Myoclonic jerks appeared during high school. His last convulsion occurred when he was a teenager. His family history was notable for absence seizures in both his sister and mother.
Physical and neurological examinations were unremarkable. Brain MRI was normal, but an EEG revealed atypical generalised spike wave (3.5-5.5 Hz). Treatment with carbamazepine was associated with GTC status epilepticus. Seizures were controlled with divalproex sodium, but he developed a macular-papular, pruritic rash forcing discontinuation of the divalproex sodium.
Treatment with phenytoin 300 mg/day and phenobarbital 100 mg/day controlled his convulsions, but he continued to have occasional absences and suffered cognitive side effects. He also took sertraline 100 mg/day for depression. Phenytoin was discontinued and the patient began lamotrigine. Lamotrigine was increased to 200 mg b.i.d. and phenobarbital was tapered over the next 6 months. He began to feel jittery and received lorazepam. He developed myoclonic jerks, and was switched from lamotrigine to levetiracetam 250 mg b.i.d. titrated up to 1000 mg b.i.d. Lorazepam was no longer needed after the patient became stabilised on levetiracetam. He has had no more absences, myoclonic jerks or convulsions for the last 9 months.
Case #3
SS was a 61-year-old right-handed man who developed myoclonic jerks and convulsions upon awakening at age 16. Family history was negative for seizures. Convulsions have been infrequent, the last one over 10 years ago. However, he continued to have myoclonic jerks and complained of decreased libido.
Physical and neurological examinations were normal except for coarsening of facial features and prolongation of end gaze nystagmus. Brain MRI showed mild leukoencephalopathy, likely due to microvascular disease. Rare fragments of generalised spike wave were present on the EEG.
Phenytoin at 400 mg/day produced a trough level of 19, but did not control the myoclonus, nor did diazepam 5 mg p.r.n. Divalproex sodium succeeded in eliminating all seizure types, but resulted in a 15 lb weight gain, which could not be corrected with diet. Divalproex sodium also produced persistent abdominal pain, unrelieved by antacids, histamine blockers or switching to Depakote Sprinkles. 
DISCUSSION
These three patients with refractory primary generalised epilepsy became seizure free when levetiracetam was added to their treatment regimen. Effective doses ranged from 1250 to 3000 mg/day. After dose titration, all of the patients tolerated the drug well.
When patients present with convulsions, physicians often fail to differentiate between primary generalised epilepsy and partial seizures with secondary generalisation. Patients may not provide a history of myoclonic jerks and absence attacks may pass undetected. However, the consequences of inaccurate diagnosis can be severe, as a number of AEDs may worsen primary generalised epilepsy 2 . In fact, Case #2, RR, developed status epilepticus after treatment with carbamazepine. Careful attention to the clinical history and EEG findings often leads to an accurate classification of seizure type. AEDs effective in partial and primary generalised seizures, such as valproate, offer an advantage in patients in whom the seizure type is unclear. Lamotrigine, topiramate and levetiracetam may also be effective in both partial and primary generalised seizures.
Although there are no published clinical trials devoted specifically to levetiracetam and primary generalised seizures, a multicentre trial of 119 refractory epilepsy patients conducted in 37 sites in the United Kingdom and Belgium between September 1993 and March 1997 study included patients with primary generalised epilepsy who received levetiracetam in doses of 2000 or 4000 mg/day. The median percentage reduction in seizure frequency was similar between both partial and primary generalised epilepsy treatment groups 13 . In the US multicentre double-blind, randomised, placebo-controlled trial, '7% had generalised seizures and unclassified epileptic seizures', but the response of this small group to treatment was not detailed 4 .
Animal data also support the use of levetiracetam for primary generalised epilepsy 14 . Levetiracetam administered intraperitoneally caused a long lasting increase in the threshold for tonic electroconvulsive seizures in mice, similar in magnitude to the effect of valproate. Levetiracetam increased the tonic electroconvulsive seizure threshold in rats as well. It was also effective against myoclonic and clonic seizures induced by intravenous pentylenetetrazol (PTZ). Its anticonvulsant potency against myoclonic seizures was approximately double that of valproate or ethosuximide.
Lamotrigine, levetiracetam, topiramate and valproate all have bioavailability that approaches 100%. The protein binding of levetiracetam is <10%, while it is 55% for lamotrigine, 15% for topiramate and 85-95% for valproate 9 . Unlike lamotrigine, topiramate and valproic acid, levetiracetam does not interact with other AEDs and only levetiracetam has no effect on hepatic enzymes. Another practical advantage of levetiracetam compared to lamotrigine and topiramate is that it can be started at a therapeutic dose of 1000 mg/day 3 . Levetiracetam can be increased to 3000 mg/day within 4 weeks 10 .
The effects of lamotrigine, levetiracetam, topiramate and valproate on the unborn foetus are currently unknown. All of these drugs are 'Category C', except for valproate, which is 'Category D'. Valproate 'is associated with the highest rate of major congenital abnormalities' of all commonly used AEDs 11 . Teratogenicity is a significant consideration in the population of patients with primary generalised epilepsy, as many are women of childbearing potential.
Topiramate has been associated with renal lithiasis (1.5%), cognitive effects and speech difficulty 12 . Like lamotrigine, it also requires slow titration, and can take weeks to months to achieve the desired dosage.
Limitations of this study include the open label design and small patient population. However, all patients had failed at least three AEDs and had well-documented clinical and EEG evidence of primary generalised epilepsy. The successful treatment of these three patients suggests that levetiracetam monotherapy may be a safe and effective choice for patients with primary generalised epilepsy, particularly those refractory to other AEDs. Given these positive responses and the attractive side-effect profile, lack of drug-drug interactions, low protein binding and prompt efficacy at starting doses, a prospective, controlled clinical trial of levetiracetam in patients with primary generalised epilepsy should be considered.
